R-PR's Taxotere Receives Nine More Approvals
Taxotere (docetaxel), Rhone-Poulenc Rorer's anticancer drug, has been cleared for use in Argentina, Israel, Pakistan, the Philippines, Romania, Russia, Slovakia and the Ukraine for the treatment of advanced breast and non-small cell lung cancer, and in Morocco for the treatment of advanced breast cancer.
The drug is now approved for use in 33 countries (including the UK and the USA), and in 15 of these it is the only product of its kind to be approved for use in non-small-cell lung cancer. Further trials are underway to ascertain Taxotere's safety and efficacy in head and neck cancer and soft tissue sarcoma, while it is being tested alone and as a multichemotherapy for the treatment of earlier stages in breast and non-small cell lung cancer.
Meanwhile, R-PR's German subsidiary is to join forces with Asta Medica for the joint marketing of R-PR's cancer products once approved. The agreement includes R-PR's Taxotere, Granozyte (lenograstim rHuG-GSF) and Campto (irinotecan) therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze